|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
FDA approve new daily pill for common skin cancer
Medical News Today
Taken in the form of a daily pill, Odomzo (generic name sonidegib) is marketed by Novartis AG — a Swiss pharma giant with U.S. headquarters in East Hanover, New Jersey.
The U.S. Food and Drug Administration (FDA) say a trial showed the drug shrank or wiped out tumors in 58 percent of patients treated.
| Share this article:
'Major player' in skin cancer genes identified
A multidisciplinary team at Yale, led by Yale Cancer Center members, has defined a subgroup of genetic mutations that are present in a significant number of melanoma skin cancer cases. Their findings shed light on an important mutation in this deadly disease, and may lead to more targeted anti-cancer therapies.
Botox may be an effective treatment for migraines
According to the National Headache Foundation, more than 37 million Americans suffer from migraine headaches. Migraines are not ordinary headaches that can be tolerated with an over-the-counter painkiller.
Migraine sufferers experience debilitating pain, often accompanied by nausea and vomiting, sensitivity to light and sound, and changes in vision.
Solar Shade SPF 50 includes a blend of natural, mineral sunscreens that glides on skin and absorbs quickly, providing broad spectrum protection to shield against sun damage and prevent photoaging. Free of dyes, fragrance, parabens, gluten, nuts and soy.
7 recent developments in psoriasis
Recent studies on psoriasis have included results finding that patients with the disease, and particularly those with psoriatic arthritis, were at increased risk of developing arrhythmia. Other recent develops reported on Healio.com/Dermatology included research on the safety of Humira for treating psoriasis and global survey findings that education is a top priority for patients with psoriasis and physicians.
Missed an issue of Warfield Weekly Update? Click here to visit Warfield Weekly Update archive page.
Teva buys Allergan's generic drug unit for $40.5B
Teva Pharmaceutical Industries said recently it has agreed to buy Allergan's generic drug unit for about $40.5 billion.
Based in Jerusalem, Teva is one of the world's largest generic drug manufacturers, and the stock-and-cash deal will help boost its pipeline, supply chain and global revenue sources, the company said.
Patients give facial filler high ratings
Cosmetic Surgery Times
Results of a recent study show that patients treated with Juvéderm Voluma XC are highly satisfied with their results.
Allergan's Juvéderm Voluma XC is a hyaluronic acid filler used for correcting age-related midface volume deficit (MVD). The study, headed by Julius Few, M.D., clinical professor of surgery in the Division of Plastic Surgery at the University of Chicago Pritzker School of Medicine, sought to get patients' input on the filler's effectiveness.
Homing in on targeted therapy for PAPA, PASH, PAPASH, and SAPHO-Syndromes
New conventional wisdom of late identifies inflammation as an important link between the development of acne lesions and several dermatologic syndromes including PAPA (pyogenic arthritis, pyoderma gangrenosum, acne), PASH (pyoderma gangrenosum, acne, suppurative hidradenitis), PAPASH (pyogenic arthritis, pyoderma gangrenosum, acne, suppurative hidradenitis), and SAPHO (synovitis, acne, pustulosis palmoplantaris, hyperostosis, osteitis).
Effective state indoor tanning regulations could lead to national regulatory framework to curtail skin cancer
Melanoma News Today
A regulatory void in urgent need of filling is establishment of a national regulatory framework for prevention and limitation of indoor tanning to help alleviate the cancer burden on the healthcare system and save billions in the cost of treating preventable skin cancer. So say two Georgetown University public health experts in a Viewpoint article published online in JAMA (Journal of the American Medical Association).
Study: Wide variation in rates of secondary cleft lip, palate surgery
Plastic Surgery Practice
For children with cleft and palate, the chances of undergoing secondary surgery varies based on where they're treated, according to a new study in Plastic and Reconstructive Surgery — Global Open.
Why skin wrinkles more around the eyes
HealthDay via Medical Xpress
Facial wrinkles — such as so-called "laugh lines" or "crow's feet" — are the bane of many aging adults. Now, new research on cadavers may offer some insight into why some skin creases are more pronounced than others.
Differences in oil-secreting glands just below the skin may help explain why forehead wrinkles are shallower than wrinkles around the outer eye, according to a research team led by Yuichi Tamatsu, of Kagoshima University Graduate School of Medical and Dental Sciences in Japan.
Missed last week's issue? See which articles your colleagues read most.
What is your Membership Worth?
Answer: More than double what you invest!
As an SDSS member, you are eligible to purchase additional memberships at a reduced rate of $51 when the first member pays $150. This offer is only good for memberships paid by credit card and will be automatically enrolled in the recurring dues feature.
NOT A MEMBER — Join Now!
NCEA-sponsored Prep Class — Aug. 24
Face & Body
Northern California Spa Conference & Expo
San Jose, California
NCEA Certified Prep Class
Monday, Aug. 24
10 a.m. to 5 p.m., Room TBD
• Members: $125
• Nonmembers: $149
Includes: Complimentary NCEA Certified Records Verification ($175 value)
*Membership status must be current on day of event.
NETT Teacher Training Long Beach — Sept. 19 — Registration Now Open
National Esthetic Teacher Training
Saturday, Sept. 19
8:45 a.m. – 5 p.m.
Room 203A Long Beach Convention Center
Early bird rate: NCEA members $99; nonmembers $129. Cost increases after Aug. 28.
Click here to for further details about member status and to register.
Philadelphia Convention Center - Oct. 24
To receive registration information, text "NCEA" to 22828.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063